Karl Storz SE

Global Rigid Endoscopes Market to 2030: Preference for Minimally Invasive Surgical Techniques over Standard Surgeries Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 30, 2023
Science, Health, Research, Medical Devices, COVID-19, Endometriosis, Conditional sentence, Karl Storz SE, Cancer, Ageing, WHO, Bone, Prevalence, Endoscopy, Gynaecology, Patient satisfaction, Kidney, Laparoscopy, Dentistry, Medical device, Hospital

The high burden of cancer, gynecological disorders, urothelial disorders, and others are contributing to the demand for surgeries, further supporting the demand for rigid endoscopes in the market.

Key Points: 
  • The high burden of cancer, gynecological disorders, urothelial disorders, and others are contributing to the demand for surgeries, further supporting the demand for rigid endoscopes in the market.
  • The COVID-19 pandemic had a negative impact on the market owing to the cancellation and decline in elective procedures during the pandemic.
  • The preference for minimally invasive surgical techniques over standard surgeries, greater patient satisfaction, enhanced economic viability, and shorter hospital stays are expected to support the demand for endoscopic surgeries and thus support the market of rigid endoscopes.
  • This high share is attributable to the significant number of endoscopic surgeries conducted in outpatient facilities, which is supporting the segment market growth.

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2022

Retrieved on: 
Thursday, March 2, 2023
Cloud, NYSE, 3D, Image, Robotics, Cholecystectomy, Investment, Growth, Regulation, Safety, GAAP, CE marking, File, Karl Storz SE, Gynaecology, Freedom, Anatomy, Bank statement, Collection, MDR, KARL, Annual report, PARK, Surgeon, U.S. FDA, Urology, European, Digital, Hospital, Cloud computing, Software, FDA, General surgery, Machine learning, LUNA, Health, Active Intelligence Pte Ltd, Security (finance), Google Cloud, CIS, ISU, PGS, RESEARCH, Pharmaceutical industry, Cryptocurrency, Dentistry, Rare-earth element, Video game, Medical device

“As we look to the future, we are incredibly excited about the opportunity we have to revolutionize patient care through Performance-Guided Surgery.

Key Points: 
  • “As we look to the future, we are incredibly excited about the opportunity we have to revolutionize patient care through Performance-Guided Surgery.
  • These instruments were commercially launched in the U.S., Japan and Europe, in the fourth quarter of 2022.
  • The Company submitted its U.S. FDA 510(k) application for pediatric clearance in the U.S. during the third quarter of 2022.
  • The Company had cash, cash equivalents, short-term and long-term investments, excluding restricted cash of approximately $74.4 million as of December 31, 2022.

Asensus Surgical Provides Corporate Update

Retrieved on: 
Tuesday, February 21, 2023
Cloud, Karl Storz SE, Hospital, Google Cloud, PARK, Anatomy, ISU, NYSE, Active Intelligence Pte Ltd, RESEARCH, Patient, KARL, Software, LUNA, Endoscopy, Drawing, ZEUS robotic surgical system, Machine learning, Digital, Surgeon, Operating, Dentistry, Medical imaging, Medical device, Intelligence

To date, we have made tremendous progress evolving robotically-assisted surgery into Digital Laparoscopy with the combination of our Senhance® Surgical System and the intelligent capabilities of our Intelligent Surgical Unit™(ISU™).

Key Points: 
  • To date, we have made tremendous progress evolving robotically-assisted surgery into Digital Laparoscopy with the combination of our Senhance® Surgical System and the intelligent capabilities of our Intelligent Surgical Unit™(ISU™).
  • However, we expect more from a surgical solution,” said Anthony Fernando, President and Chief Executive Officer of Asensus.
  • The LUNA Surgical System is Asensus’ next generation digital surgery platform that is poised to revolutionize the way surgery is performed.
  • As part of this agreement, KARL STORZ intends to market and sell Asensus’ Intelligent Surgical Unit as a standalone device together with their IMAGE1 S™ Imaging system and OR1™ integration solution.

KARL STORZ Receives Innovative Technology Designation from Vizient for TIPCAM1 Rubina with ARTip SOLO Robotic Assistance

Retrieved on: 
Friday, December 23, 2022
Oncology, Software, Medical Devices, Hardware, Hospitals, Data Management, Technology, Practice Management, Veterinary, Nursing, Managed Care, Medical Supplies, Cardiology, General Health, Surgery, Robotics, Health, Health Technology, Surgeon, Patient safety, Karl Storz SE, The Chartered Institute of Ergonomics and Human Factors, ONE, Environment, The Queen's Award for Enterprise: Innovation (Technology) (2011), Artipic, Robotics, Academic health science centre, Safety, MD, Health, Multimedia, KARL, Laparoscopy, 3D, Workflow, Hospital, Zenith Contract Services, Pharmaceutical industry, Medical imaging, Medicine, Medical device, Vizient, Inc., Oncology, Software, Medical Devices, Hardware, Hospitals, Data Management, Technology, Practice Management, Veterinary, Nursing, Managed Care, Medical Supplies, Cardiology, General Health, Surgery, Robotics, Health, Health Technology

KARL STORZ Endoscopy-America, Inc., proudly announces its TIPCAM®1 Rubina® with ARTip® SOLO robotic assistance has received an Innovative Technology designation from Vizient, Inc. , the largest healthcare performance improvement company in the country.

Key Points: 
  • KARL STORZ Endoscopy-America, Inc., proudly announces its TIPCAM®1 Rubina® with ARTip® SOLO robotic assistance has received an Innovative Technology designation from Vizient, Inc. , the largest healthcare performance improvement company in the country.
  • KARL STORZ exhibited TIPCAM1 Rubina with ARTip SOLO at the Vizient Innovative Technology Exchange on Oct. 17 in Dallas, Texas.
  • The ARTip® SOLO robotic camera guidance system allows the operating surgeon to maintain stability and precise control of the field of view.
  • Congratulations to KARL STORZ.”
    For more detailed information, about TIPCAM®1 Rubina® and ARTip® SOLO technology, visit karlstorznetwork1.com .

Global Endometrial Ablation Devices Market Analysis Report 2022: A $990.9 Million Market in 2021 - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Medical Devices, Health, Awareness, Endometrial ablation, Growth, Population, The Cooper Companies, Mergers and acquisitions, Olympus Corporation, Hospital, MEA, PCOD, Radiofrequency ablation, Uterus, Industry, COVID-19, SCSI Peripheral Device Type, Menstruation, Johnson & Johnson, Ethicon Inc., End user, Workforce, Incidence, Education, Investment, USD, Woman, Karl Storz SE, Medtronic, Prevalence, Mergers & Acquisitions, Lithium, Birth control, Retail, Hysterectomy

The Global Endometrial Ablation Devices Market was valued at USD 990.9 Million in the year 2021 with the Americas region leading the regional market share.

Key Points: 
  • The Global Endometrial Ablation Devices Market was valued at USD 990.9 Million in the year 2021 with the Americas region leading the regional market share.
  • The Asia Pacific Endometrial Ablation Devices market is predicted to be the hotspot and the most lucrative region for market participants worldwide.
  • The report analyses the Endometrial Ablation Devices Market by Device Type (Radiofrequency Ablators, Thermal balloon Ablators, Cryoablation Devices, Hydrothermal Ablators, Electrical Ablators and Others).
  • The Global Endometrial Ablation Devices Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).

Photocure ASA: Results for the third quarter of 2022

Retrieved on: 
Wednesday, November 2, 2022
EBIT, EBITDA, CEO, Outpatient surgery, Mission statement, Centers for Medicare & Medicaid Services, Patient, CMS, NOK, CFO, Cropping system, Karl Storz SE, IFRS, Center for Medicare and Medicaid Innovation, Company, CET, BLC, Hexyl aminolevulinate hydrochloride, History, ASA, Ambulatory Surgery Center Association, Cystoscopy, Center, ASC, APM, Health insurance, Photocure, Medicare

"Photocure delivered Hexvix/Cysview revenue growth of 12%, driven by higher unit sales in both North America and Europe in addition to the net favorable effect of foreign exchange.

Key Points: 
  • "Photocure delivered Hexvix/Cysview revenue growth of 12%, driven by higher unit sales in both North America and Europe in addition to the net favorable effect of foreign exchange.
  • Photocure reported total group revenues of NOK 106.8 million in the third quarter of 2022 (NOK 87.4 million), and EBITDA* of NOK 4.7 million (NOK -0.2 million), driven by the increase in product revenue and a milestone payment from Asieris.
  • EBIT was NOK -1.4 million (-6.3 million) and the cash balance at the end of Q3 2022 was NOK 283.9 million.
  • Photocure announced the commercial availability of Karl Storz's new high-definition blue light rigid system in the United States late in the quarter.

Photocure ASA: Results for the third quarter of 2022

Retrieved on: 
Wednesday, November 2, 2022
EBIT, EBITDA, CEO, Outpatient surgery, Mission statement, Centers for Medicare & Medicaid Services, Patient, CMS, NOK, CFO, Cropping system, Karl Storz SE, IFRS, Center for Medicare and Medicaid Innovation, Company, CET, BLC, Hexyl aminolevulinate hydrochloride, History, ASA, Ambulatory Surgery Center Association, Cystoscopy, Center, ASC, APM, Health insurance, Photocure, Medicare

"Photocure delivered Hexvix/Cysview revenue growth of 12%, driven by higher unit sales in both North America and Europe in addition to the net favorable effect of foreign exchange.

Key Points: 
  • "Photocure delivered Hexvix/Cysview revenue growth of 12%, driven by higher unit sales in both North America and Europe in addition to the net favorable effect of foreign exchange.
  • Photocure reported total group revenues of NOK 106.8 million in the third quarter of 2022 (NOK 87.4 million), and EBITDA* of NOK 4.7 million (NOK -0.2 million), driven by the increase in product revenue and a milestone payment from Asieris.
  • EBIT was NOK -1.4 million (-6.3 million) and the cash balance at the end of Q3 2022 was NOK 283.9 million.
  • Photocure announced the commercial availability of Karl Storz's new high-definition blue light rigid system in the United States late in the quarter.

Laparoscopic Instruments Market: Laparoscopic laser thermal systems to create growth prospects for Laparoscopic Instruments Market

Retrieved on: 
Tuesday, November 1, 2022
Marketing, KG, Awareness, Growth, Vascular closure device, Sample, Pancreatic cancer, Population, Karl Storz SE, Olympus Corporation, Gallbladder, Method, Pain, Laparotomy, Research, Obesity, Industry, Bleeding, Risk, Hospital, Medicine, US missile defense system in Asia-Pacific Region, Endometriosis, Colorectal surgery, Energy, Government, Prostate cancer, CAGR, Endoscopy, Disease, USD, Colon, Review, Product, History, Patient, Kidney, Bariatric surgery, General surgery, Stryker Corporation, Percussion section, Uterine fibroid, Medical imaging, Health insurance, Medical device, Healthcare, Laparoscopy, Laparoscopy, Application

Secondary research is used to identify key companies in the Laparoscopic Instruments market, while primary and secondary research is used to determine their market revenues.

Key Points: 
  • Secondary research is used to identify key companies in the Laparoscopic Instruments market, while primary and secondary research is used to determine their market revenues.
  • This has resulted in an increase in demand for surgery, being the driving force for the laparoscopic instruments market growth.
  • Laparoscopic Instruments Regional Market Insights:
    North America held the largest share in Laparoscopic Instruments Market for the year 2021 accounting for 37.6 percent of the total sales.
  • By Product, the Laparoscopic Instruments Market is segmented into Laparoscopes, Energy Systems, Trocars, Closure Devices, Suction/ Irrigation Device, Insufflation Device, Robot-Assisted Systems and Hand Access Instruments
    By Application, the Laparoscopic Instruments Market is segmented into Colorectal Surgery, Bariatric Surgery, Urological Surgery, Gynaecological Surgery, General Surgery and Other Surgeries
    By End-Users, the Laparoscopic Instruments Market is segmented into Hospital, Clinic and Ambulatory
    Laparoscopic Instruments Market Key Players:

Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology

Retrieved on: 
Thursday, September 8, 2022
KARL, Technology, Man, Bladder cancer, Cell, Oslo Stock Exchange, CIS, Population, POWER, NMIBC, Photocure, Patient, Blue Light, Blue, Cancer, Urinary bladder, Endoscopy, Department, PMU, Department of Urology, University of Virginia, Hospital, General manager, PDD, Death, Solution, Recurrence, Paracelsus Medical University, TURBT, Neoplasm, OSE, Veterinary medicine, BLC, Karl Storz SE, Diagnosis, Cystoscopy, Carcinoma in situ, Prevalence, Medical imaging, Pharmaceutical industry, Urology, MIBC, T4

Over 400 registered delegates could see how the "IMAGE1 S SAPHIRA" system improves visualization of bladder cancer via practical case studies.

Key Points: 
  • Over 400 registered delegates could see how the "IMAGE1 S SAPHIRA" system improves visualization of bladder cancer via practical case studies.
  • Manufactured and commercialized by KARL STORZ, the new Blue Light system is the next generation, improving the Blue Light experience and providing next-level visualization.
  • Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall.NMIBC remains in the inner layer of cells lining the bladder.
  • Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC).

Blue Light Cystoscopy continues to make news at AUA 2022

Retrieved on: 
Wednesday, May 18, 2022
American Urological Association, OSE, USC, Flexible, CIS, Cell, Carcinoma in situ, Conference, AUA, University, Cancer, Prevalence, Bladder cancer, TURBT, Initial, Man, BLC, Calendar, Death, Solution, Photocure, Karl Storz SE, Oslo Stock Exchange, FDA, Recurrence, WLC, Program, Congress, SUO, ASA, Education, Population, Hexyl aminolevulinate hydrochloride, Neoplasm, Cystoscopy, Patient, BC, Technology, NMIBC, Physician, Diagnosis, Pharmaceutical industry, Medical imaging, Urology, T4, MIBC

Both the Photocure and Karl Storz exhibit booths provided information to AUA attendees on the New Blue Light equipment, for which interest was strong.

Key Points: 
  • Both the Photocure and Karl Storz exhibit booths provided information to AUA attendees on the New Blue Light equipment, for which interest was strong.
  • The New Blue Light equipment from Karl Storz was prominently displayed on the exhibition floor, as urologists visited both the Photocure and Karl Storz booths to inquire about the New Blue Light System, the next generation equipment in bladder cancer detection.
  • This year's AUA program also once again featured NMIBC topics including Blue Light Cystoscopy.
  • Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC).